Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway

BACKGROUND: Cyclin-dependent kinase 9 (CDK9) is a promising prognostic marker and therapeutic target in cancers. Bufalin is an effective anti-tumour agent; however, the clinical application of bufalin is limited due to its high toxicity. Acetyl-bufalin, the bufalin prodrug, was designed and synthesi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Lehe, Zhou, Feng, Zhuang, Yan, Liu, Yanan, Xu, Lingyuan, Zhao, Haiyang, Xiang, Youqun, Dai, Xuanxuan, Liu, Zhiguo, Huang, Xiaoying, Wang, Liangxing, Zhao, Chengguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851395/
https://www.ncbi.nlm.nih.gov/pubmed/33122847
http://dx.doi.org/10.1038/s41416-020-01135-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851395/
https://www.ncbi.nlm.nih.gov/pubmed/33122847
http://dx.doi.org/10.1038/s41416-020-01135-6

Ejemplares similares